As part of the collaboration, both the parties will identify and co-fund translational research projects with leading academic medical centers within the CTI network.
JMF noted that the collaboration with Pfizer will strengthen its commitment to provide better treatments for patients with immunological diseases.
The Jeffrey Modell Centers Network (JMCN) has 600 physicians at 248 academic institutions, in 206 cities in 79 countries.
CTI senior vice-president and chief scientific officer Anthony Coyle said: "Accelerating drug discovery is the goal of every CTI collaboration and this agreement aligns with two of our core therapeutic areas, immunology and rare diseases, where we have leading expertise and a long history in research and bringing treatments to patients.
"With a deeply committed partner like the Jeffrey Modell Foundation, we have an opportunity to leverage our respective expertise to help enhance our understanding of the complex immune system, which plays a key role in many rare diseases."
According to JMF, the collaboration with CTI represents its first alliance with a biopharmaceutical company.
Jeffrey Modell Foundation co-founder Vicki Modell said: "JMF’s expertise in Primary Immunodeficiency and extensive network of collaborators, combined with Pfizer’s impressive research and development capabilities has the potential to identify and advance novel research projects.
"Together, we hope to make meaningful advancements in our understanding of immunological diseases."
JMF is dedicated to early diagnosis, meaningful treatments, and ultimately cures through research, physician education, public awareness, advocacy, patient support and newborn screening.
Image: Pfizer world headquarters. Photo: courtesy of Jim.henderson.